| |
|
|
|
Seeweekly news
|
2005-11-22 |
|
|
Clarient Enters Agreement With Eli Lilly and Company |
Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, announced today that it has entered into an agreement with pharmaceutical leader Eli Lilly and Company. Clarient's BioPharma business unit will provide various biopharmaceutical research services.
"We look forward to supporting Lilly with our scientific expertise utilizing advanced technology platforms to provide a solution for the development of companion diagnostics for emerging therapies," said Clarient's Medical Director, Kenneth J. Bloom, M.D.
Clarient's President and CEO Ron Andrews said, "The Company's strategy in the biopharmaceutical sector involves providing fee-based services and technologies to those companies engaged in the drug discovery process. The revenue provided by those relationships is complemented by additional opportunities for growth in the future as companion diagnostics are developed, based on Clarient technologies, for new cancer drugs." |
|
|
|
|
|
|
